

## Health-related quality of life among older adults following acute hospitalization

### Journal

Quality of Life Research

### Authors

Eirin Guldsten Robinson<sup>1</sup>, Hanna Gyllensten<sup>2</sup>, Anne Gerd Granas<sup>1</sup>, Kjell H Halvorsen<sup>3</sup>, Beate Hennie Garcia<sup>3,4</sup>

### Affiliations

<sup>1</sup> Department of Pharmacy, University of Oslo, 0316 Oslo, Norway.

<sup>2</sup> Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

<sup>3</sup> Department of Pharmacy, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway.

<sup>4</sup> Hospital Pharmacy of North Norway Trust, Tromsø, Norway

**Correspondence to:** e.g.robinson@farmasi.uio.no

<b>Table S1 Problems in the EQ-5D dimensions, index scores and EQ-VAS in the non-long stayers (n=222)</b>	<b>2</b>
<b>Table S2 Problems in the EQ-5D dimensions, index scores and EQ-VAS in the long stayers (n=63)</b>	<b>3</b>
<b>Table S3 Results of multivariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the non-long stayers (n=222)</b>	<b>4</b>
<b>Table S4 Results of multivariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the long stayers (n=63)</b>	<b>5</b>
<b>Table S5 Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the full population (n=285)</b>	<b>6</b>
<b>Table S6 Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the non-long stayers (n=222)</b>	<b>7</b>
<b>Table S7 Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the long stayers (n=63)</b>	<b>8</b>
<b>Table S8 Results of univariable and final multivariable mixed model regressions of index scores for the non-long stayers (n=222) and long stayers (n=63)</b>	<b>9</b>
<b>Table S9 Results of univariable and final multivariable mixed model regressions of EQ-5D VAS for the non-long stayers (n=222) and long stayers (n=63)</b>	<b>10</b>

**Table S1** Problems in the EQ-5D dimensions, index scores and EQ-VAS in the non-long stayers (n=222)

	Discharge N=222		1 month N=217		6 months N=211		12 months N=205	
	Intervention group n=104	Control group n=116	Intervention group n=105	Control group n=112	Intervention group n=101	Control group n=110	Intervention group n=99	Control group n=106
<b>Mobility, n (%)</b>								
No problems	29 (27.4)	31 (26.7)	34 (32.4)	28 (25.0)	32 (31.7)	21 (19.1)	26 (26.3)	16 (15.1)
Moderate problems	68 (64.2)	75 (64.7)	62 (59.1)	70 (62.5)	60 (59.4)	70 (63.6)	58 (58.6)	67 (63.2)
Extreme problems	7 (6.6)	10 (8.6)	6 (5.7)	6 (5.4)	3 (3.0)	8 (7.3)	6 (6.1)	8 (7.6)
Reporting any problems <sup>a</sup>	75 (70.8)	85 (73.3)	68 (64.8)	76 (67.9)	63 (62.4)	78 (70.9)	64 (64.7)	75 (70.8)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	8 (7.1)	6 (5.9)	11 (10.0)	9 (9.1)	15 (14.2)
<b>Self-care, n (%)</b>								
No problems	69 (65.1)	74 (63.8)	70 (66.7)	74 (66.1)	78 (77.2)	75 (68.2)	64 (64.7)	69 (65.1)
Moderate problems	28 (26.4)	30 (25.9)	28 (26.7)	24 (21.4)	15 (14.9)	17 (15.5)	24 (24.2)	14 (13.2)
Extreme problems	7 (6.6)	12 (10.3)	4 (3.8)	6 (5.4)	2 (2.0)	6 (5.5)	2 (2.0)	8 (7.6)
Reporting any problems <sup>a</sup>	35 (33.0)	42 (36.2)	32 (30.5)	30 (26.8)	17 (16.8)	23 (20.9)	26 (26.3)	22 (20.8)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	8 (7.1)	6 (5.9)	12 (10.9)	9 (9.1)	15 (14.2)
<b>Usual activities, n (%)</b>								
No problems	32 (30.2)	35 (30.2)	42 (40.0)	29 (25.9)	34 (33.7)	29 (36.4)	34 (34.3)	28 (26.4)
Moderate problems	44 (41.5)	46 (39.7)	43 (41.0)	53 (47.3)	46 (45.5)	47 (42.7)	40 (40.4)	41 (38.7)
Extreme problems	28 (26.4)	35 (30.2)	17 (16.2)	22 (19.6)	15 (14.9)	21 (19.1)	16 (16.2)	22 (20.8)
Reporting any problems <sup>a</sup>	72 (67.9)	81 (69.8)	60 (57.1)	75 (67.0)	61 (60.4)	68 (61.8)	56 (56.6)	63 (59.4)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	8 (7.1)	6 (5.9)	13 (11.8)	9 (9.1)	15 (14.2)
<b>Pain/discomfort, n (%)</b>								
No problems	33 (31.1)	42 (36.2)	34 (32.4)	44 (39.3)	36 (35.6)	30 (27.3)	26 (26.3)	27 (25.5)
Moderate problems	58 (54.7)	57 (49.1)	57 (54.3)	49 (43.8)	48 (47.5)	50 (45.5)	53 (53.5)	49 (46.2)
Extreme problems	13 (12.3)	17 (14.7)	11 (10.5)	11 (9.8)	11 (10.9)	18 (16.4)	11 (11.1)	15 (14.2)
Reporting any problems <sup>a</sup>	71 (67.0)	74 (63.8)	68 (64.8)	60 (53.6)	59 (58.4)	68 (61.8)	64 (64.6)	64 (60.4)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	8 (7.1)	6 (5.9)	12 (10.9)	9 (9.1)	15 (14.2)
<b>Anxiety/depression, n (%)</b>								
No problems	63 (59.4)	68 (58.6)	63 (60.0)	67 (59.8)	59 (58.4)	56 (51.0)	55 (55.6)	57 (53.8)
Moderate problems	35 (33.0)	39 (33.6)	36 (34.3)	32 (28.6)	35 (34.7)	37 (33.6)	34 (34.3)	29 (27.4)
Extreme problems	6 (5.7)	9 (7.8)	3 (2.9)	4 (3.6)	1 (1.0)	5 (4.6)	1 (1.0)	4 (3.8)
Reporting any problems <sup>a</sup>	41 (38.7)	48 (41.4)	39 (37.1)	36 (32.1)	36 (35.6)	42 (38.2)	35 (35.4)	33 (31.1)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	9 (8.0)	6 (5.9)	12 (10.9)	9 (9.1)	16 (15.1)
<b>Any dimension, n (%)</b>								
No problems	8 (7.6)	12 (10.3)	11 (10.5)	12 (10.7)	12 (11.9)	8 (7.3)	5 (5.1)	9 (8.5)
Moderate problems	57 (53.8)	55 (47.4)	64 (61.0)	62 (55.4)	57 (56.4)	58 (52.7)	59 (59.6)	52 (49.1)
Extreme problems	39 (36.8)	49 (42.2)	27 (25.7)	30 (26.8)	26 (25.7)	33 (30.0)	26 (26.3)	30 (28.3)
Reporting any problems <sup>a</sup>	96 (90.6)	104 (89.7)	91 (86.7)	92 (82.1)	83 (82.2)	91 (82.7)	85 (85.9)	82 (77.4)
Missing	2 (1.9)	0 (0.0)	3 (2.9)	8 (7.1)	6 (5.9)	11 (10.0)	9 (9.1)	15 (14.2)
<b>EQ-5D-3L index score<sup>b</sup></b>	0.511	0.491	0.567	0.529	0.559	0.451	0.501	0.436
<b>EQ-5D-3L VAS score<sup>b</sup></b>	60.29	56.27	61.86	60.71	64.08	58.92	62.87	57.41

<sup>a</sup>Reporting any problems is the sum of moderate problems and extreme problems.<sup>b</sup>Unadjusted

Abbreviations: EQ-VAS, EuroQol visual analogue scale

**Table S2** Problems in the EQ-5D dimensions, index scores and EQ-VAS in the long stayers (n=63)

	Discharge N=63		1 month N=60		6 months N=57		12 months N=54	
	Intervention group n=42	Control group n=21	Intervention group n=40	Control group n=20	Intervention group n=38	Control group n=19	Intervention group n=35	Control group n=19
<b>Mobility, n (%)</b>								
No problems	6 (14.3)	1 (4.8)	7 (17.5)	1 (5.0)	3 (7.9)	2 (10.5)	4 (11.1)	2 (10.5)
Moderate problems	33 (78.6)	17 (81.0)	24 (60.0)	16 (80.0)	23 (60.5)	15 (79.0)	14 (38.9)	12 (63.2)
Extreme problems	3 (7.1)	3 (14.3)	2 (5.0)	1 (5.0)	1 (2.6)	0 (0.0)	4 (11.1)	1 (5.3)
Reporting any problems <sup>a</sup>	36 (85.7)	20 (95.2)	26 (65.0)	17 (85.0)	24 (63.2)	15 (79.0)	18 (50.0)	13 (68.4)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	2 (10.5)	14 (38.9)	4 (21.1)
<b>Self-care, n (%)</b>								
No problems	24 (57.1)	9 (42.9)	17 (42.5)	11 (55.0)	17 (44.7)	9 (47.4)	13 (36.1)	9 (47.4)
Moderate problems	15 (35.7)	6 (28.6)	14 (35.0)	5 (25.0)	7 (18.4)	7 (36.8)	5 (13.9)	5 (26.3)
Extreme problems	3 (7.1)	6 (28.6)	2 (5.0)	2 (10.0)	3 (7.9)	1 (5.3)	4 (11.1)	1 (5.3)
Reporting any problems <sup>a</sup>	18 (42.9)	12 (57.1)	16 (40.0)	7 (35.0)	10 (26.3)	8 (42.1)	9 (25.0)	6 (31.6)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	2 (10.5)	14 (38.9)	4 (21.1)
<b>Usual activities, n (%)</b>								
No problems	8 (19.1)	3 (14.3)	6 (15.0)	1 (5.0)	4 (10.5)	2 (10.5)	4 (11.1)	1 (5.3)
Moderate problems	22 (52.4)	8 (38.1)	14 (35.0)	8 (40.0)	15 (39.5)	12 (63.2)	11 (30.6)	11 (57.9)
Extreme problems	12 (28.6)	10 (47.6)	13 (32.5)	9 (45.0)	8 (21.1)	3 (15.8)	7 (19.4)	3 (15.8)
Reporting any problems <sup>a</sup>	34 (81.0)	18 (85.7)	27 (67.5)	17 (85.0)	23 (60.5)	15 (79.0)	18 (50.0)	14 (73.7)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	2 (10.5)	14 (38.9)	4 (21.1)
<b>Pain/discomfort, n (%)</b>								
No problems	15 (35.7)	10 (47.6)	9 (22.5)	4 (20.0)	9 (23.7)	4 (21.1)	6 (16.7)	2 (10.5)
Moderate problems	22 (52.4)	9 (42.9)	20 (50.0)	11 (55.0)	13 (34.2)	10 (52.6)	10 (27.8)	10 (52.6)
Extreme problems	5 (11.9)	2 (9.5)	4 (10.0)	3 (15.0)	5 (13.2)	2 (10.5)	6 (16.7)	3 (15.8)
Reporting any problems <sup>a</sup>	27 (64.3)	11 (52.4)	24 (60.0)	14 (70.0)	18 (47.4)	12 (63.2)	16 (44.4)	13 (68.4)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	3 (15.8)	14 (38.9)	4 (21.1)
<b>Anxiety/depression, n (%)</b>								
No problems	33 (78.6)	8 (38.1)	23 (57.5)	11 (55.0)	16 (42.1)	8 (42.1)	15 (41.7)	8 (42.1)
Moderate problems	7 (16.7)	11 (52.4)	8 (20.0)	5 (25.0)	9 (23.7)	7 (36.8)	4 (11.1)	7 (36.8)
Extreme problems	2 (4.8)	2 (9.5)	2 (5.0)	2 (10.0)	2 (5.3)	1 (5.3)	3 (8.3)	0 (0.0)
Reporting any problems <sup>a</sup>	9 (21.4)	13 (61.9)	10 (25.0)	7 (35.0)	11 (29.0)	8 (42.1)	7 (19.4)	7 (36.8)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	3 (15.8)	14 (38.9)	4 (21.1)
<b>Any dimension, n (%)</b>								
No problems	3 (7.1)	0 (0.0)	3 (7.5)	0 (0.0)	3 (7.9)	0 (0.0)	2 (5.6)	0 (0.0)
Moderate problems	22 (52.4)	9 (42.9)	14 (35.0)	6 (30.0)	12 (31.6)	12 (63.2)	9 (25.0)	9 (47.4)
Extreme problems	17 (40.5)	12 (57.1)	16 (40.0)	12 (60.0)	12 (31.6)	5 (26.3)	11 (30.6)	6 (31.6)
Reporting any problems <sup>a</sup>	39 (92.9)	21 (100.0)	30 (75.0)	18 (90.0)	24 (63.2)	17 (89.5)	20 (55.6)	15 (79.0)
Missing	0 (0.0)	0 (0.0)	7 (17.5)	2 (10.0)	11 (29.0)	2 (10.5)	14 (38.9)	4 (21.1)
<b>EQ-5D-3L index score<sup>b</sup></b>	0.508	0.366	0.394	0.330	0.342	0.459	0.242	0.362
<b>EQ-5D-3L VAS score<sup>b</sup></b>	56.15	51.83	52.85	49.12	52.72	58.53	52.97	54.85

<sup>a</sup>Reporting any problems is the sum of moderate problems and extreme problems.<sup>b</sup>Unadjusted

Abbreviations: EQ-VAS, EuroQol visual analogue scale

**Table S3** Results of multivariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the non-long stayers (n=222)

	Mobility		Self-care		Usual activities		Pain/Discomfort		Anxiety/Depression	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Constant	0.32 (0.10 – 1.02)	0.055	0.11 (0.02 – 0.79)	0.029	0.00 (0.00 – 0.01)	<0.001	0.55 (0.26 – 1.18)	0.127	0.08 (0.03 – 0.20)	<0.001
Intervention group	0.61 (0.26 – 1.42)	0.253	1.10 (0.53 – 2.27)	0.793	0.70 (0.03 – 1.47)	0.352	1.12 (0.62 – 2.00)	0.707	0.93 (0.43 – 2.04)	0.860
Time (reference: discharge)										
1 month	0.81 (0.44 – 1.49)	0.499	0.72 (0.41 – 1.29)	0.271	0.75 (0.42 – 1.34)	0.331	0.78 (0.47 – 1.28)	0.328	0.77 (0.44 – 1.36)	0.369
6 months	1.18 (0.62 – 2.21)	0.616	<b>0.31 (0.16 – 0.59)</b>	<b>&lt;0.001</b>	0.95 (0.52 – 1.73)	0.858	0.98 (0.59 – 1.62)	0.924	1.17 (0.66 – 2.07)	0.593
12 months	2.14 (1.09 – 4.17)	0.026	0.72 (0.39 – 1.32)	0.286	0.99 (0.54 – 1.81)	0.965	1.40 (0.82 – 2.39)	0.219	0.98 (0.55 – 1.77)	0.957
Study ward 1	<b>4.08 (1.54 – 10.76)</b>	<b>0.005</b>	<b>2.49 (0.00 – 6.22)</b>	<b>0.050</b>	<b>2.57 (1.07 – 6.16)</b>	<b>0.035</b>	NS	NS	NS	NS
Age when included <sup>a</sup>	NS	NS	NS	NS	<b>1.10 (1.03 – 1.18)</b>	<b>0.004</b>	NS	NS	NA	NA
Sex Female	NS	NS	NA	NA	NS	NS	<b>2.54 (1.39 – 4.65)</b>	<b>0.002</b>	<b>3.19 (1.41 – 7.21)</b>	<b>0.005</b>
Level of education >12 years	NA	NA	<b>2.26 (1.08 – 4.71)</b>	<b>0.030</b>	NA	NA	NA	NA	NA	NA
Home-dwelling before included	NS	NS	<b>0.10 (0.02 – 0.53)</b>	<b>0.006</b>	NS	NS	NA	NA	NS	NS
Living alone before included	NS	NS	NS	NS	NS	NS	NA	NA	NA	NA
Home-care services	<b>6.17 (2.37 – 16.09)</b>	<b>&lt;0.001</b>	<b>12.59 (5.26 – 30.14)</b>	<b>&lt;0.001</b>	<b>3.49 (1.52 – 8.04)</b>	<b>0.003</b>	NS	NS	NS	NS
Number of medications total <sup>a</sup>	<b>1.17 (1.07 – 1.29)</b>	<b>0.001</b>	<b>1.09 (1.01 – 1.17)</b>	<b>0.018</b>	<b>1.26 (1.15 – 1.37)</b>	<b>&lt;0.001</b>	<b>1.12 (1.06 – 1.19)</b>	<b>&lt;0.001</b>	NS	NS
Handling own medications	NS	NS	NS	NS	NS	NS	NA	NA	NS	NS
Multidose adherence aid	NS	NS	NS	NS	NS	NS	NA	NA	<b>2.89 (1.18 – 7.06)</b>	<b>0.020</b>
Hypertension	NA	NA	NA	NA	NA	NA	NS	NS	NA	NA
Asthma or COPD	NA	NA	NS	NS	NS	NS	NS	NS	NA	NA
Atrial fibrillation	NS	NS	NS	NS	NS	NS	NA	NA	<b>2.50 (1.03 – 6.05)</b>	<b>0.042</b>
Diabetes	NS	NS	NS	NS	NS	NS	NA	NA	<b>2.70 (1.00 – 7.25)</b>	<b>0.049</b>
Heart failure	NS	NS	NS	NS	NS	NS	NA	NA	NS	NS
Renal failure	NA	NA	NA	NA	NA	NA	NA	NA	NS	NS
Anxiety / depression	NA	NA	NA	NA	NA	NA	NS	NS	<b>28.27 (6.36 – 125.53)</b>	<b>&lt;0.001</b>
Dementia	NA	NA	NS	NS	NA	NA	<b>0.08 (0.01 – 0.49)</b>	<b>0.007</b>	NA	NA
Charlson Comorbidity Index <sup>b</sup>	NS	NS	NS	NS	NS	NS	NA	NA	NA	NA

<sup>a</sup> Continuous variable

<sup>b</sup> Tested in a separate model from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.

**Table S4** Results of multivariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the long stayers (n=63)

	Mobility		Self-care		Usual activities		Pain/Discomfort		Anxiety/Depression	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Constant	7.25 (0.74 – 70.56)	0.088	0.05 (0.01 – 0.35)	0.002	0.84 (0.09 – 8.26)	0.882	1.31 (0.37 – 4.67)	0.677	0.04 (0.00 – 0.35)	0.004
Intervention group	0.57 (0.11 – 2.99)	0.502	1.13 (0.33 – 3.89)	0.842	0.54 (0.10 – 2.97)	0.482	1.09 (0.46 – 2.61)	0.843	0.25 (0.05 – 1.19)	0.082
Time (reference: discharge)										
1 month	0.55 (0.14 – 2.11)	0.382	0.95 (0.35 – 2.56)	0.914	1.54 (0.38 – 6.20)	0.544	2.23 (0.90 – 5.56)	0.085	0.89 (0.28 – 2.82)	0.843
6 months	0.97 (0.22 – 4.25)	0.963	0.70 (0.24 – 2.02)	0.511	1.57 (0.36 – 6.76)	0.548	1.82 (0.71 – 4.66)	0.213	2.39 (0.72 – 7.94)	0.155
12 months	0.62 (0.14 – 2.67)	0.519	1.00 (0.32 – 3.08)	0.995	1.94 (0.40 – 9.41)	0.410	3.37 (1.13 – 10.00)	0.029	1.37 (0.39 – 4.82)	0.623
Study ward Ward 1	NA		NS		<b>21.28 (2.30 – 196.75)</b>	<b>0.007</b>	NA		NA	
Age when included <sup>a</sup>	NS		NS		NS		NS		NA	
Sex Female	NA		NA		NA		NA		NS	
Level of education >12 years	NA		NS		NS		NA		NA	
Home-dwelling before included	NS		NA		NA		NA		NA	
Living alone before included	NA		NA		NS		NA		NA	
Home-care services	NS		<b>6.5 (1.68 – 25.22)</b>	<b>0.007</b>	NS		NA		NS	
Number of medications total <sup>a</sup>	<b>1.20 (1.01 – 1.42)</b>	<b>0.040</b>	<b>1.17 (1.03 – 1.34)</b>	<b>0.014</b>	NS		<b>1.11 (1.02 – 1.22)</b>	<b>0.015</b>	<b>1.32 (1.12 – 1.57)</b>	<b>0.001</b>
Handling own medications	NA		NS		NS		NA		NS	
Multidose adherence aid	NA		NS		NS		NA		NS	
Hypertension	NA		NA		NS		<b>0.40 (0.17 – 0.91)</b>	<b>0.029</b>	NS	
Asthma or COPD	NA		NA		<b>40.29 (1.42 – 1144.25)</b>	<b>0.030</b>	NS		NS	
Atrial fibrillation	NA		NS		NA		<b>0.31 (0.12 – 0.78)</b>	<b>0.013</b>	NS	
Diabetes	NA		NA		NA		NA		NA	
Heart failure	NA		NS		NA		NA		NA	
Renal failure	NA		NS		NA		NA		NA	
Anxiety / depression	NA		NA		NA		NS		<b>16.71 (1.40 – 199.84)</b>	<b>0.026</b>
Dementia	NA		NA		NA		NA		NA	
Charlson Comorbidity Index <sup>b</sup>	NS		NS		NA		NA		NA	

<sup>a</sup> Continuous variable

<sup>b</sup> Tested separately from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.

**Table S5** Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the full population (n=285)

	Mobility		Self-care		Usual activities		Pain/Discomfort		Anxiety/Depression	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Constant	16.41 (7.31 – 36.84)	<0.001	0.36 (0.20 – 0.67)	0.001	10.02 (4.71 – 1.27)	<0.001	2.31 (1.46 – 3.65)	<0.001	0.48 (0.26 – 0.90)	0.022
Intervention group	0.60 (0.27 – 1.35)	0.217	1.07 (0.52 – 2.20)	0.858	0.73 (0.33 – 1.62)	0.435	1.16 (0.69 – 1.97)	0.588	0.64 (0.30 – 1.37)	0.250
Time (reference: discharge)										
1 month	0.69 (0.40 – 1.21)	0.199	0.73 (0.44 – 1.20)	0.215	0.74 (0.43 – 1.27)	0.274	0.99 (0.64 – 1.53)	0.968	0.80 (0.48 – 1.33)	0.392
6 months	1.02 (0.57 – 1.83)	0.948	0.36 (0.21 – 0.62)	<0.001	0.90 (0.51 – 1.58)	0.705	1.12 (0.72 – 1.76)	0.645	1.33 (0.79 – 2.22)	0.283
12 months	1.57 (0.85 – 2.90)	0.148	0.71 (0.42 – 1.21)	0.213	0.94 (0.53 – 1.67)	0.839	<b>1.68 (1.04 – 2.69)</b>	<b>0.034</b>	1.05 (0.62 – 1.78)	0.866
Study ward Ward 1	<b>9.08 (3.52 – 23.43)</b>	<b>&lt;0.001</b>	<b>7.51 (3.00 – 18.81)</b>	<b>&lt;0.001</b>	<b>11.33 (4.36 – 29.46)</b>	<b>&lt;0.001</b>	0.91 (0.49 – 1.70)	0.772	<b>3.11 (1.27 – 7.61)</b>	<b>0.013</b>
Age when included (continuous)	<b>1.17 (1.09 – 1.25)</b>	<b>&lt;0.001</b>	<b>1.10 (1.03 – 1.16)</b>	<b>0.003</b>	<b>1.20 (81.12 – 1.29)</b>	<b>&lt;0.001</b>	0.99 (0.95 – 1.03)	0.752	<b>0.96 (0.90 – 1.02)</b>	<b>0.188</b>
Sex Female	1.47 (0.64 – 3.37)	0.367	0.91 (0.43 – 1.91)	0.806	<b>2.03 (0.89 – 4.66)</b>	<b>0.093</b>	<b>2.34 (1.36 – 4.03)</b>	<b>0.002</b>	<b>3.67 (1.68 – 8.03)</b>	<b>0.001</b>
Level of education >12 years	1.03 (0.45 – 2.35)	0.939	1.08 (0.52 – 2.25)	0.826	<b>0.53 (0.23 – 1.21)</b>	<b>0.132</b>	1.09 (0.63 – 1.86)	0.765	0.70 (0.33 – 1.52)	0.369
Home-dwelling before included	<b>0.05 (0.00 – 0.60)</b>	<b>0.018</b>	<b>0.20 (0.05 – 0.89)</b>	<b>0.034</b>	<b>0.02 (0.00 – 0.37)</b>	<b>0.008</b>	0.69 (0.23 – 2.13)	0.523	<b>2.50 (0.54 – 11.63)</b>	<b>0.242</b>
Living alone before included	<b>2.77 (1.21 – 6.37)</b>	<b>0.016</b>	<b>2.30 (1.10 – 4.84)</b>	<b>0.027</b>	<b>4.83 (2.13 – 10.98)</b>	<b>&lt;0.001</b>	1.20 (0.79 – 0.69)	0.519	1.16 (0.54 – 2.49)	0.703
Home-care services	<b>13.10 (5.59 – 30.67)</b>	<b>&lt;0.001</b>	<b>17.44 (8.34 – 36.47)</b>	<b>&lt;0.001</b>	<b>16.62 (7.17 – 38.52)</b>	<b>&lt;0.001</b>	<b>1.62 (0.96 – 2.74)</b>	<b>0.071</b>	<b>3.33 (1.54 – 7.17)</b>	<b>0.002</b>
Number of medications total	<b>1.26 (1.15 – 1.38)</b>	<b>&lt;0.001</b>	<b>1.21 (1.13 – 1.30)</b>	<b>&lt;0.001</b>	<b>1.37 (1.25 – 1.51)</b>	<b>&lt;0.001</b>	<b>1.13 (1.08 – 1.19)</b>	<b>&lt;0.001</b>	<b>1.17 (1.09 – 1.26)</b>	<b>&lt;0.001</b>
Handling own medications	<b>0.10 (0.043 – 0.24)</b>	<b>&lt;0.001</b>	<b>0.08 (0.04 – 0.18)</b>	<b>&lt;0.001</b>	<b>0.06 (0.03 – 0.14)</b>	<b>&lt;0.001</b>	1.05 (0.62 – 1.79)	0.854	<b>0.21 (0.10 – 0.46)</b>	<b>&lt;0.001</b>
Multidose adherence aid	<b>6.62 (2.53 – 17.32)</b>	<b>&lt;0.001</b>	<b>5.68 (2.57 – 12.54)</b>	<b>&lt;0.001</b>	<b>12.19 (4.63 – 32.07)</b>	<b>&lt;0.001</b>	<b>1.46 (0.82 – 2.61)</b>	<b>0.201</b>	<b>4.89 (2.12 – 11.31)</b>	<b>&lt;0.001</b>
Hypertension	0.96 (0.43 – 2.15)	0.916	0.98 (0.48 – 2.01)	0.959	1.42 (0.64 – 3.18)	0.390	1.20 (0.71 – 2.05)	0.489	0.67 (0.31 – 1.41)	0.289
Asthma or COPD	1.42 (0.58 – 3.49)	0.439	<b>1.72 (0.78 – 3.81)</b>	<b>0.178</b>	<b>3.32 (1.33 – 8.25)</b>	<b>0.010</b>	<b>1.92 (1.06 – 3.46)</b>	<b>0.030</b>	1.20 (0.52 – 2.76)	0.670
Atrial fibrillation	<b>2.83 (1.01 – 7.23)</b>	<b>0.030</b>	<b>2.20 (0.98 – 4.91)</b>	<b>0.055</b>	<b>3.32 (1.32 – 8.32)</b>	<b>0.011</b>	1.08 (0.59 – 1.95)	0.807	<b>3.24 (1.38 – 7.58)</b>	<b>0.007</b>
Diabetes	<b>5.54 (1.82 – 16.89)</b>	<b>0.003</b>	<b>3.17 (1.30 – 7.78)</b>	<b>0.011</b>	<b>5.76 (1.94 – 17.06)</b>	<b>0.002</b>	1.09 (0.56 – 2.10)	0.808	<b>3.01 (1.14 – 7.93)</b>	<b>0.026</b>
Heart failure	<b>2.89 (0.88 – 9.47)</b>	<b>0.079</b>	<b>4.01 (1.47 – 10.94)</b>	<b>0.007</b>	<b>2.50 (0.79 – 7.90)</b>	<b>0.117</b>	0.91 (0.43 – 1.91)	0.806	<b>2.03 (0.76 – 6.37)</b>	<b>0.144</b>
Renal failure	1.91 (0.61 – 6.07)	0.268	1.46 (0.54 – 3.93)	0.455	1.26 (0.41 – 3.84)	0.682	1.25 (0.60 – 2.61)	0.547	0.62 (0.22 – 1.76)	0.367
Anxiety / depression	1.20 (0.30 – 4.78)	0.793	<b>2.38 (0.70 – 8.15)</b>	<b>0.167</b>	<b>2.40 (0.58 – 9.83)</b>	<b>0.225</b>	<b>2.60 (1.00 – 6.71)</b>	<b>0.048</b>	<b>43.18 (10.90 – 171.00)</b>	<b>&lt;0.001</b>
Dementia	1.85 (0.19 – 18.47)	0.601	<b>7.83 (1.09 – 56.22)</b>	<b>0.041</b>	2.31 (0.23 – 22.68)	0.473	<b>0.17 (0.04 – 0.72)</b>	<b>0.016</b>	0.36 (0.05 – 2.89)	0.339
Charlson Comorbidity Index*	<b>1.50 (1.18 – 1.91)</b>	<b>&lt;0.001</b>	<b>1.46 (1.20 – 1.77)</b>	<b>&lt;0.001</b>	<b>1.41 (1.12 – 1.79)</b>	<b>0.004</b>	1.05 (0.92 – 1.21)	0.470	1.05 (0.86 – 1.29)	0.610

<sup>a</sup> Continuous variable

<sup>b</sup> Tested separately from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.

**Table S6** Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the non-long stayers (n=222)

	Mobility		Self-care		Usual activities		Pain/Discomfort		Anxiety/Depression	
	Univariable regression OR (95% CI)	p-value	Univariable regression OR (95% CI)	p-value	Univariable regression OR (95% CI)	p-value	Univariable regression OR (95% CI)	p-value	Univariable regression OR (95% CI)	p-value
Constant	12.59 (5.28 – 30.02)	<0.001	0.29 (0.15 – 0.58)	0.001	7.49 (3.44 – 16.29)	<0.001	2.58 (1.51 – 4.40)	<0.001	0.44 (0.22 – 0.87)	0.019
Intervention group	0.50 (0.20 – 1.26)	0.142	1.01 (0.44 – 2.31)	0.99	0.60 (0.25 – 1.46)	0.262	1.21 (0.64 – 2.29)	0.548	0.92 (0.40 – 2.14)	0.851
Time (reference: discharge)										
1 month	0.76 (0.41 – 1.40)	0.374	0.69 (0.39 – 1.23)	0.211	0.69 (0.38 – 1.24)	0.213	0.78 (0.47 – 1.28)	0.323	0.76 (0.43 – 1.34)	0.349
6 months	1.09 (0.58 – 2.05)	0.794	0.30 (0.16 – 0.57)	<0.001	0.86 (0.47 – 1.58)	0.629	0.97 (0.58 – 1.62)	0.911	1.14 (0.65 – 2.03)	0.636
12 months	1.96 (1.00 – 3.85)	0.049	0.67 (0.37 – 1.22)	0.192	0.89 (0.48 – 1.65)	0.715	1.39 (0.81 – 2.36)	0.232	0.98 (0.54 – 1.75)	0.935
Study ward Ward 1	<b>9.61 (3.35 – 27.60)</b>	<b>&lt;0.001</b>	<b>6.15 (2.24 – 16.91)</b>	<b>&lt;0.001</b>	<b>8.57 ( 3.13 – 23.47)</b>	<b>&lt;0.001</b>	1.01 (0.49 – 2.29)	0.989	<b>3.35 (1.27 – 8.82)</b>	<b>0.014</b>
Age when included (continuous)	<b>1.17 (1.08 – 1.27)</b>	<b>&lt;0.001</b>	<b>1.07 (1.00 – 1.15)</b>	<b>0.047</b>	<b>1.21 ( 1.12 – 1.30)</b>	<b>&lt;0.001</b>	1.01 (0.95 – 1.06)	0.813	0.97 (0.90 – 1.04)	0.370
Sex Female	<b>1.97 (0.76 – 5.06)</b>	<b>0.161</b>	1.00 (0.42 – 2.35)	0.994	<b>2.04 (0.82 – 5.05)</b>	<b>0.124</b>	<b>2.60 (1.56 – 5.63)</b>	<b>0.001</b>	<b>4.18 (1.74 – 10.05)</b>	<b>0.001</b>
Level of education >12 years	1.03 (0.41 – 2.63)	0.943	<b>1.66 (0.72 – 3.82)</b>	<b>0.237</b>	0.65 (0.26 – 1.60)	0.346	0.94 (0.49 – 1.78)	0.848	0.66 (0.28 – 1.56)	0.342
Home-dwelling before included	<b>0.05 (0.00 – 1.07)</b>	<b>0.056</b>	<b>0.12 (0.02 – 0.88)</b>	<b>0.038</b>	<b>0.05 (0.00 – 0.74)</b>	<b>0.030</b>	0.55 (0.11 – 2.69)	0.458	<b>0.29 (0.04 – 2.12)</b>	<b>0.220</b>
Living alone before included	<b>4.00 (1.54 – 10.40)</b>	<b>0.004</b>	<b>2.26 (0.96 – 5.32)</b>	<b>0.061</b>	<b>4.96 (2.02 – 12.21)</b>	<b>&lt;0.001</b>	1.32 (0.69 – 2.52)	0.398	0.82 (0.35 – 1.91)	0.645
Home-care services	<b>16.69 (6.25 – 44.57)</b>	<b>&lt;0.001</b>	<b>17.87 (7.65 – 41.72)</b>	<b>&lt;0.001</b>	<b>16.12 (6.48 – 40.15)</b>	<b>&lt;0.001</b>	<b>1.78 (0.95 – 3.34)</b>	<b>0.072</b>	<b>3.20 (1.36 – 7.55)</b>	<b>0.008</b>
Number of medications total	<b>1.28 (1.15 – 1.40)</b>	<b>&lt;0.001</b>	<b>1.20 (1.11 – 1.31)</b>	<b>&lt;0.001</b>	<b>1.37 (1.24 – 1.52)</b>	<b>&lt;0.001</b>	<b>1.15 (1.08 – 1.22)</b>	<b>&lt;0.001</b>	<b>1.12 (1.03 – 1.22)</b>	<b>0.006</b>
Handling own medications	<b>0.09 (0.03 – 0.23)</b>	<b>&lt;0.001</b>	<b>0.08 (0.03 – 0.20)</b>	<b>&lt;0.001</b>	<b>0.06 (0.02 – 0.15)</b>	<b>&lt;0.001</b>	1.01 (0.53 – 1.90)	0.984	<b>0.26 (0.11 – 0.62)</b>	<b>0.002</b>
Multidose adherence aid	<b>9.49 (3.06 – 29.39)</b>	<b>&lt;0.001</b>	<b>6.54 (2.57 – 16.67)</b>	<b>&lt;0.001</b>	<b>13.40 (4.54 – 39.51)</b>	<b>&lt;0.001</b>	1.45 (0.72 – 2.95)	0.301	<b>5.774 (2.19 – 15.06)</b>	<b>&lt;0.001</b>
Hypertension	0.91 (0.36 – 2.25)	0.830	0.88 (0.38 – 2.02)	0.762	1.16 (0.48 – 2.80)	0.739	<b>1.63 (0.87 – 3.05)</b>	<b>0.129</b>	0.89 (0.38 – 2.06)	0.781
Asthma or COPD	1.50 (0.55 – 4.06)	0.429	<b>2.17 (0.88 – 5.34)</b>	<b>0.093</b>	<b>2.91 (1.10 – 7.75)</b>	<b>0.032</b>	<b>1.76 (0.88 – 3.52)</b>	<b>0.108</b>	0.77 (0.31 – 1.93)	0.578
Atrial fibrillation	<b>3.91 (1.34 – 11.41)</b>	<b>0.013</b>	<b>1.77 (0.70 – 4.47)</b>	<b>0.228</b>	<b>3.92 (1.43 – 10.77)</b>	<b>&lt;0.001</b>	1.52 (0.74 – 3.09)	0.253	<b>3.33 (1.29 – 8.61)</b>	<b>0.013</b>
Diabetes	<b>6.81 (1.92 – 24.10)</b>	<b>0.003</b>	<b>3.18 (1.13 – 8.93)</b>	<b>0.029</b>	<b>4.17 (1.31 – 13.25)</b>	<b>0.016</b>	0.97 (0.44 – 2.14)	0.949	<b>3.50 (1.18 – 10.40)</b>	<b>0.024</b>
Heart failure	<b>3.25 (0.80 – 13.16)</b>	<b>0.098</b>	<b>3.75 (1.12 – 12.57)</b>	<b>0.032</b>	<b>2.65 (0.72 – 9.84)</b>	<b>0.145</b>	0.90 (0.36 – 2.26)	0.821	<b>1.82 (0.53 – 6.29)</b>	<b>0.343</b>
Renal failure	2.17 (0.55 – 8.61)	0.269	0.82 (0.24 – 2.78)	0.746	0.97 (0.27 – 3.50)	0.959	1.01 (0.40 – 2.53)	0.980	<b>0.41 (0.12 – 1.41)</b>	<b>0.157</b>
Anxiety / depression	1.20 (0.25 – 5.79)	0.817	2.28 (0.54 – 9.56)	0.260	1.55 (0.33 – 7.25)	0.580	<b>2.34 (0.76 – 7.18)</b>	<b>0.137</b>	<b>45.38 (9.48 – 217.28)</b>	<b>&lt;0.001</b>
Dementia	0.75 (0.05 – 11.36)	0.834	<b>9.43 (0.80 – 111.63)</b>	<b>0.075</b>	0.86 (0.06 – 11.88)	0.913	<b>0.07 (0.01 – 0.47)</b>	<b>0.006</b>	0.10 (0.01 – 1.53)	0.099
Charlson Comorbidity Index*	<b>1.48 (1.13 – 1.94)</b>	<b>0.004</b>	<b>1.42 (1.15 – 1.77)</b>	<b>0.001</b>	<b>1.40 (1.09 – 1.80)</b>	<b>0.008</b>	1.05 (0.89 – 1.23)	0.568	1.05 (0.85 – 1.31)	0.642

\* Continuous variable

<sup>b</sup> Tested separately from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.

**Table S7** Results of univariable multi-level logistic regression models of EQ-5D dimensions (no problem versus problem (moderate or extreme)) for the long stayers (n=63)

	Mobility		Self-care		Usual activities		Pain/Discomfort		Anxiety/Depression	
	Simple regression		Simple regression		Simple regression		Simple regression		Simple regression	
	OR (95% CI))	p-value	OR (95% CI))	p-value	OR (95% CI))	p-value	OR (95% CI))	p-value	OR (95% CI))	p-value
Constant	52.50 (6.43 – 428.30)	<0.001	0.99 (0.28 – 3.50)	0.992	40.04 (3.57 – 448.56)	0.003	1.79 (0.71 – 4.52)	0.217	0.91 (0.19 – 4.35)	0.906
Intervention group	0.39 (0.07 – 2.28)	0.295	0.76 (0.19 – 3.12)	0.704	0.50 (0.07 – 3.87)	0.508	0.93 (0.35 – 2.51)	0.892	0.15 (0.02 – 1.06)	0.057
Time (reference: discharge)										
1 month	0.53 (0.14 – 2.07)	0.360	0.89 (0.33 – 2.41)	0.817	1.31 (0.32 – 5.56)	0.708	2.25 (0.89 – 5.69)	0.086	0.93 (0.29 – 2.95)	0.897
6 months	0.92 (0.20 – 4.12)	0.911	0.66 (0.23 – 1.90)	0.438	1.38 (0.30 – 6.30)	0.681	1.75 (0.67 – 4.55)	0.250	2.35 (0.70 – 7.84)	0.166
12 months	0.58 (0.13 – 2.57)	0.475	0.94 (0.31 – 2.90)	0.917	1.71 (0.33 – 8.76)	0.521	3.23 (1.08 – 9.69)	0.036	1.31 (0.37 – 4.62)	0.670
Study ward Ward 1	2.78 (0.36 – 23.47)	0.326	<b>9.83 (1.07 – 89.84)</b>	<b>0.043</b>	<b>17.76 (1.72 – 183.44)</b>	<b>0.016</b>	0.44 (0.10 – 1.90)	0.273	2.33 (0.20 – 27.54)	0.503
Age when included (continuous)	<b>1.11 (0.99 – 1.26)</b>	<b>0.077</b>	<b>1.13 (1.01 – 1.26)</b>	<b>0.032</b>	<b>1.10 (0.94 – 1.28)</b>	<b>0.247</b>	<b>0.95 (0.87 – 1.02)</b>	<b>0.167</b>	0.92 (0.80 – 1.07)	0.279
Sex Female	0.47 (0.08 – 2.69)	0.393	0.84 (0.21 – 3.45)	0.810	2.73 (0.39 – 19.11)	0.311	1.08 (0.40 – 2.92)	0.882	<b>3.01 (0.51 – 17.61)</b>	<b>0.222</b>
Level of education >12 years	0.88 (0.18 – 4.29)	0.974	<b>0.27 (0.06 – 1.14)</b>	<b>0.074</b>	<b>0.16 (0.02 – 1.12)</b>	<b>0.065</b>	1.62 (0.62 – 4.28)	0.327	0.68 (0.11 – 4.03)	0.668
Home-dwelling before included	<b>0.15 (0.01 – 3.20)</b>	<b>0.222</b>	0.80 (0.11 – 5.78)	0.822	1 (omitted)		1.05 (0.26 – 4.28)	0.941	0.63 (0.05 – 7.32)	0.710
Living alone before included	0.42 (0.70 – 2.51)	0.340	2.00 (0.49 – 8.18)	0.332	<b>3.02 (0.46 – 19.74)</b>	<b>0.247</b>	0.80 (0.30 – 2.14)	0.658	1.25 (0.22 – 7.27)	0.803
Home-care services	<b>2.57 (0.54 – 12.30)</b>	<b>0.236</b>	<b>11.22 (2.68 – 46.93)</b>	<b>0.001</b>	<b>8.62 (1.29 – 57.47)</b>	<b>0.026</b>	1.22 (0.46 – 3.21)	0.693	<b>5.65 (0.88 – 36.09)</b>	<b>0.067</b>
Number of medications total	<b>1.20 (1.01 – 1.42)</b>	<b>0.040</b>	<b>1.24 (1.08 – 1.42)</b>	<b>0.002</b>	<b>1.33 (1.09 – 1.61)</b>	<b>0.005</b>	<b>1.09 (1.00 – 1.20)</b>	<b>0.062</b>	<b>1.37 (1.15 – 1.64)</b>	<b>0.001</b>
Handling own medications	0.41 (0.08 – 2.08)	0.283	<b>0.13 (0.03 – 0.50)</b>	<b>0.003</b>	<b>0.16 (0.02 – 1.13)</b>	<b>0.066</b>	1.33 (0.49 – 3.58)	0.576	<b>0.08 (0.01 – 0.054)</b>	<b>0.009</b>
Multidose adherence aid	1.02 (0.20 – 5.27)	0.984	<b>2.55 (0.63 – 10.30)</b>	<b>0.188</b>	<b>4.02 (0.52 – 30.71)</b>	<b>0.180</b>	1.46 (0.55 – 3.92)	0.448	<b>3.38 (0.60 – 19.20)</b>	<b>0.169</b>
Hypertension	1.10 (0.22 – 5.44)	0.907	1.29 (0.34 – 4.94)	0.710	<b>3.53 (0.50 – 25.11)</b>	<b>0.207</b>	<b>0.40 (0.16 – 0.99)</b>	<b>0.048</b>	<b>0.21 (0.04 – 1.21)</b>	<b>0.081</b>
Asthma or COPD	2.06 (0.31 – 13.76)	0.455	1.04 (0.22 – 5.06)	0.958	<b>32.15 (0.91 – 1138.49)</b>	<b>0.057</b>	<b>3.33 (1.07 – 10.40)</b>	<b>0.038</b>	<b>7.03 (0.98 – 50.45)</b>	<b>0.052</b>
Atrial fibrillation	0.70 (0.12 – 3.91)	0.682	<b>3.51 (0.77 – 15.97)</b>	<b>0.104</b>	1.22 (0.15 – 10.12)	0.850	<b>0.30 (0.14 – 1.08)</b>	<b>0.069</b>	<b>3.35 (0.47 – 23.66)</b>	<b>0.226</b>
Diabetes	2.26 (0.28 – 18.49)	0.448	2.53 (0.48 – 13.45)	0.275	1 (Empty)		1.44 (0.44 – 4.72)	0.547	1.36 (0.17 – 11.01)	0.773
Heart failure	1.17 (0.16 – 8.42)	0.879	<b>3.20 (0.60 – 17.00)</b>	<b>0.172</b>	0.98 (0.10 – 9.66)	0.984	0.93 (0.29 – 2.97)	0.898	5.22 (0.60 – 45.44)	0.134
Renal failure	0.67 (0.11 – 4.10)	0.666	<b>2.81 (0.58 – 13.7)</b>	<b>0.199</b>	1.16 (0.12 – 11.01)	0.895	1.91 (0.60 – 6.12)	0.273	1.90 (0.25 – 14.17)	0.533
Anxiety / depression	1.01 (0.08 – 12.77)	0.992	2.60 (0.27 – 24.04)	0.408	1 (Empty)		<b>3.77 (0.64 – 22.18)</b>	<b>0.142</b>	<b>45.18 (2.52 – 808.17)</b>	<b>0.010</b>
Dementia	1 (Empty)		4.63 (0.22 – 96.35)	0.322	1 (Empty)		0.96 (0.11 – 8.20)	0.971	6.06 (0.13 – 287.44)	0.360
Charlson Comorbidity Index*	<b>1.40 (0.86 – 2.30)</b>	<b>0.180</b>	<b>1.52 (0.97 – 2.36)</b>	<b>0.065</b>	1.27 (0.66 – 2.43)	0.470	1.09 (0.81 – 1.47)	0.576	0.99 (0.59 – 1.69)	0.984

<sup>a</sup> Continuous variable<sup>b</sup> Tested separately from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.



**Table S8** Results of univariable and final multivariable mixed model regressions of index scores for the non-long stayers (n=222) and long stayers (n=63)

	Non-long stayers (n=222)				Long stayers (n=222)			
	Univariable regression		Multivariable regression		Univariable regression		Multivariable regression	
	$\beta$ (95% CI)	p-value	$\beta$ (95% CI)	p-value	$\beta$ (95% CI)	p-value	$\beta$ (95% CI)	p-value
Constant	0.47 (0.41 – 0.53)	<0.001	0.54 (0.37 – 0.70)	<0.001	0.46 (0.34 – 0.58)	<0.001	0.76 (0.61 – 0.90)	<0.001
Intervention group	0.06 (-0.02 – 0.13)	0.156	0.03 (-0.3 – 0.9)	0.363	0.003 (-0.12 – 0.13)	0.966	-0.05 (-0.15 – 0.05)	0.310
Time (reference: discharge)								
1 month	0.05 (0.003 – 0.09)	0.037	<b>0.05 (0.00 – 0.09)</b>	<b>0.040</b>	-0.09 (-0.19 – 0.1)	0.086	-0.08 (-0.18 – 0.02)	0.310
6 months	0.002 (-0.04 – 0.05)	0.925	0.001 (-0.04 – 0.05)	0.954	-0.08 (-0.118 – 0.02)	0.138	-0.08 (-0.18 – 0.03)	0.140
12 months	-0.03 (-0.09 – -0.01)	0.146	-0.03 (-0.08 – 0.01)	0.124	-0.17 (-0.28 – -0.07)	0.001	<b>-0.17 (-0.27 – -0.07)</b>	<b>0.001</b>
Study ward 1	<b>-0.16 (-0.25 – 0.13)</b>	<b>0.117</b>		NS	<b>-0.11 (-0.29 – 0.06)</b>	<b>0.206</b>		NS
Age when included <sup>a</sup>	<b>-0.01 (-0.02 – -0.01)</b>	<b>0.001</b>		NS	-0.004 (-0.02 – 0.01)	0.362		NA
Sex Female	<b>-0.05 (-0.13 – 0.03)</b>	<b>0.225</b>		NS	<b>-0.08 (-0.21 – 0.04)</b>	<b>0.192</b>		NS
Level of education >12 years	-0.01 (-0.09 – 0.07)	0.800		NA	<b>0.12 (0.00 – 0.24)</b>	<b>0.049</b>		NS
Home-dwelling before included	<b>0.27 (-0.09 – 0.44)</b>	<b>0.003</b>	<b>0.23 (0.08 – 0.38)</b>	<b>0.003</b>	0.05 (-0.13 – 0.23)	0.593		NA
Living alone before included	-0.03 (-0.11 – 0.05)	0.417		NA	0.01 (-0.11 – 0.14)	0.903		NA
Home-care services	<b>-0.26 (-0.33 – -0.19)</b>	<b>&lt;0.001</b>	<b>-0.15 (-0.23 – -0.07)</b>	<b>&lt;0.001</b>	<b>-0.20 (-0.32 – -0.08)</b>	<b>0.001</b>		NS
Number of medications total <sup>a</sup>	<b>-0.03 (-0.03 – -0.02)</b>	<b>&lt;0.001</b>	<b>-0.02 (-0.02 – -0.01)</b>	<b>&lt;0.001</b>	<b>-0.03 (-0.04 – -0.02)</b>	<b>&lt;0.001</b>	<b>-0.02 (-0.03 – -0.01)</b>	<b>&lt;0.001</b>
Handling own medications	<b>0.25 (0.18 – 0.32)</b>	<b>&lt;0.001</b>		NS	<b>0.21 (0.09 – 0.32)</b>	<b>&lt;0.001</b>		NS
Multidose adherence aid	<b>-0.26 (-0.34 – -0.18)</b>	<b>&lt;0.001</b>	<b>-0.10 (-0.19 – -0.02)</b>	<b>0.014</b>	<b>-0.21 (-0.32 – -0.10)</b>	<b>&lt;0.001</b>	<b>-0.13 (-0.24 – -0.03)</b>	<b>0.011</b>
Hypertension	-0.02 (-0.10 – 0.06)	0.596		NA	0.06 (-0.06 – 0.18)	0.300		NA
Asthma or COPD	<b>-0.08 (-0.16 – 0.01)</b>	<b>0.072</b>		NS	<b>-0.17 (-0.30 – -0.03)</b>	<b>0.017</b>		NS
Atrial fibrillation	-0.05 (-0.14 – 0.04)	0.276		NA	0.003 (-0.13 – 0.14)	0.965		NA
Diabetes	<b>-0.12 (-0.21 – -0.02)</b>	<b>0.017</b>		NS	0.02(-0.14 – 0.17)	0.826		NA
Heart failure	<b>-0.08 (-0.20 – 0.03)</b>	<b>0.148</b>		NS	-0.04 (-0.19 – 0.11)	0.600		NA
Renal failure	0.02 (-0.10 – 0.13)	0.753		NA	-0.06 (-0.20 – 0.08)	0.408		NA
Anxiety / depression	<b>-0.14 (-0.28 – -0.01)</b>	<b>0.032</b>		NS	<b>-0.16 (-0.35 – 0.04)</b>	<b>0.117</b>		NS
Dementia	-0.11 (-0.33 – 0.11)	0.316		NA	<b>-0.20 (-0.44 – 0.04)</b>	<b>0.103</b>		NS
Charlson Comorbidity Index <sup>b</sup>	<b>-0.03 (-0.05 – -0.02)</b>	<b>0.001</b>		NS	<b>-0.03 (-0.07 – 0.00)</b>	<b>0.090</b>		NS

<sup>a</sup> Continuous variable

<sup>b</sup> Tested in a separate model from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; CI, confidence interval;  $\beta$ , regression coefficient; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.

**Table S9** Results of univariable and final multivariable mixed model regressions of EQ-5D VAS for the non-long stayers (n=222) and long stayers (n=63)

	Non-long stayers (n=222)			Long stayers (n=222)			Long stayers (n=63)		
	Univariable regression coefficient (95% CI)	p-value	Multivariable regression coefficient (95% CI)	p-value	Univariable regression coefficient (95% CI)	p-value	Multivariable regression coefficient (95% CI)	p-value	
Constant	56.37 (52.84 – 59.91)	<0.001	103.18 (76.06 – 130.30)	<0.001	53.67 (46.80 – <b>60.55</b> )	<0.001	68.65 (59.41 – 77.89)	<0.001	
Intervention group	3.82 (-0.74 – 8.39)	0.101	<b>4.02 (0.11 – 7.93)</b>	<b>0.044</b>	1.44 (-6.39 – 9.26)	0.719	1.39 (-8.28 – 5.49)	0.692	
Time (reference: discharge)									
1 month	3.01 (0.24 – 5.77)	0.033	2.56 (-0.21 – 5.33)	0.070	-3.02 (-9.25 – 3.19)	0.340	-3.70 (-9.89 – 2.50)	0.242	
6 months	3.18 (0.33 – 6.03)	0.029	2.58 (-0.26 – 5.43)	0.075	-0.11 (-6.74 – 6.52)	0.973	-0.77 (-7.35 – 5.80)	0.817	
12 months	1.87 (-1.12 – 4.86)	0.219	1.07 (-1.93 – 4.06)	0.485	-1.02 (-8.27 – 6.22)	0.782	-1.51-8.69 – 5.68	0.681	
Study ward 1	<b>-9.58 (-14.61 – -4.55)</b>	<b>&lt;0.001</b>	<b>-7.19 (-11.85 – -2.54)</b>	<b>0.002</b>	<b>-11.81 (-21.29 – -2.33)</b>	<b>0.015</b>		NS	
Age when included <sup>a</sup>	<b>-0.67 (-1.03 – -0.30)</b>	<b>&lt;0.001</b>	<b>-0.38 (-0.72 – -0.03)</b>	<b>&lt;0.001</b>	<b>-0.52 (-1.12 – 0.07)</b>	<b>0.084</b>		NS	
Sex Female	<b>-3.50 (-8.16 – 1.16)</b>	<b>0.141</b>		NS	1.63 (-6.13 – 9.39)	0.680		NA	
Level of education >12 years	-0.97 (-5.65 – 3.70)	0.684		NA	<b>10.12 (2.88 – 17.38)</b>	<b>0.006</b>		NS	
Home-dwelling before included	6.13 (-6.23 – 18.48)	0.331		NA	3.66 (-7.30 – 14.61)	0.513		NA	
Living alone before included	<b>-3.44 (-8.04 – 1.16)</b>	<b>0.143</b>		NS	-3.71 (-11.23 – 3.82)	0.334		NA	
Home-care services	<b>-9.78 (-14.19 – -5.37)</b>	<b>&lt;0.001</b>		NS	<b>-11.66 (-18.61 – -4.72)</b>	<b>0.001</b>	<b>-8.89 (-15.74 – -2.05)</b>	<b>0.011</b>	
Number of medications total <sup>a</sup>	<b>-1.24 (-1.62 – -0.87)</b>	<b>&lt;0.001</b>	<b>-1.16 (-1.52 – -0.81)</b>	<b>&lt;0.001</b>	<b>-1.11 (-1.76 – -0.46)</b>	<b>0.001</b>	<b>-0.85 (-1.50 – -0.21)</b>	<b>0.010</b>	
Handling own medications	<b>8.14 (3.63 – 12.66)</b>	<b>&lt;0.001</b>		NS	<b>9.29 (1.94 – 16.65)</b>	<b>0.013</b>		NS	
Multidose adherence aid	<b>-10.62 (-15.60 – -5.65)</b>	<b>&lt;0.001</b>		NS	<b>-10.90 (-18.49 – -3.31)</b>	<b>0.005</b>		NS	
Hypertension	0.81 (-3.77 – 5.38)	0.730		NA	2.26 (-5.21 – 9.73)	0.554		NA	
Asthma or COPD	-1.75 (-6.69 – 3.18)	0.486		NA	<b>-6.66 (-14.68 – 1.36)</b>	<b>0.104</b>		NS	
Atrial fibrillation	<b>-3.85 (-9.01 – 1.32)</b>	<b>0.144</b>		NS	-3.38 (-12.40 – 5.64)	0.463		NA	
Diabetes	<b>-5.24 (-10.78 – 0.29)</b>	<b>0.063</b>		NS	1.83 (-7.72 – 11.38)	0.707		NA	
Heart failure	<b>-8.38 (-15.21 – -1.54)</b>	<b>0.016</b>		NS	-5.03 (-14.19 – 4.14)	0.282		NA	
Renal failure	-0.34 (-6.84 – 6.16)	0.919		NA	-1.88 (-10.79 – 7.04)	0.680		NA	
Anxiety / depression	<b>-5.68 (-13.89 – 2.53)</b>	<b>0.175</b>		NS	-3.69 (-16.01 – 8.63)	0.557		NA	
Dementia	0.51 (-15.13 – 16.14)	0.949		NA	-5.54 (-26.33 – 15.24)	0.601		NA	
Charlson Comorbidity Index <sup>b</sup>	<b>-1.24 (-2.37 – -0.13)</b>	<b>0.029</b>		NS	-0.41 (-2.74 – 1.91)	0.728		NA	

<sup>a</sup> Continuous variable

<sup>b</sup> Tested in a separate model from other comorbidities.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; CI, confidence interval; β, regression coefficient; NS, not significant in multivariate regression; NA, not applicable based on univariate regression.